Author Topic: Commentary on whether DMTs can be safely discontinued in stable RRMS patients  (Read 36 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8594
  • MS diagnosed 1980
  • Location: Pacific Northwest
From Multiple Sclerosis Journal, August 1, 2017--Dr. John Corboy's commentary on a debate about whether disease-modifying therapies can be safely discontinued in patients with stable RRMS.

One significant section of the article:

In both relapsing and progressive MS trials, age, recent relapses, and baseline active lesions on magnetic resonance imaging (MRI) scans are predictive of response to multiple DMTs, yet both relapses and new MRI lesions are noted to decline dramatically with aging. Taken as a whole, there simply are little or no data that starting to use
any of the presently available DMTs has much benefit in typical older patients, perhaps over 55, especially if they do not have a recent history of relapses
or active MRI scans.

Also this:

Finally, the apparent reduction in efficacy of the presently available DMTs in the aging MS patient, at a time when many are experiencing progressive disability,
should be a reminder that there remains a critical need to develop therapies directed toward this patient population.
« Last Edit: July 28, 2017, 04:40:44 pm by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post October 21, 2016, 02:53:46 pm
by agate
0 Replies
Last post June 11, 2018, 07:48:30 pm
by agate
0 Replies
Last post December 13, 2018, 09:02:08 pm
by agate
0 Replies
Last post May 23, 2019, 09:25:17 pm
by agate
0 Replies
Last post February 15, 2020, 09:23:59 pm
by agate